So, given Leronlimab was called into service as th

Quote:

---

So, given Leronlimab was called into service as the 4th line of defense,
and given many of our patients received less than 700 mg -

Could we make an educated guess on what the expected outcomes would be if we were 1st line treatment at 700 mg?

---

Any guess would not be educated. With a detailed breakdown of each patient it might be possible to figure out why some of those in the 525mg/700mg group did spectacularly. Outside of dose size even knowing what mechanisms of action Cytodyn thinks are probable would be helpful. That is if they are novel.

With fourth line treatment and only 700mg - At 12 months between the 350mg group and the 525mg/700mg group there is an increase of around 35% in survival with the 525mg/700mg group. The 525mg/700mg group would have been hindered a bit because 4 patients escalated from 350mg to 525mg. Over a 12 month time period you should see at least a 35% survivability with 700mg. Over a longer period you'd see an increased survivability if for no other reason than that more patients were alive at 12 months. At 4 years the percentages would most likely look a bit better than they do now.

With 700mg and first line treatment that's unknown. Starting treatment at first diagnose of the disease and continued dosing until treatment failure or death should increase lifespan by a lot. As far as being cancer free, we don't know whether the failure is due to genetic variations that leronlimab doesn't address, leronlimab being used too late in disease progression or some unknown factor. Maybe Cytodyn knows what it is but the rest of us are left in the dark for now.